Comparative Pharmacology
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus SUBVENITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus SUBVENITE.
DIPHENYLAN SODIUM vs SUBVENITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
100 mg orally every 8 hours
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
None Documented
None Documented
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing.
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%.
Category C
Category C
Antiepileptic
Antiepileptic